Skip to content

Blog

Version chaos in publication management

No-Login External Collaboration for Publication Management

What do Medical Affairs teams gain when external authors and reviewers are brought into one secure, auditable workflow? The email arrives with the ...
AI chatbots vs AI workflows

The AI Medical Affairs Hasn't Imagined Yet: Workflows, Not Chatbots

Drawing on the 2026 AI in Medical Affairs Industry Benchmark Survey and a senior leadership roundtable convened at MAPS Americas 2026.
Process debt in IIS approvals

Process Debt in IIS Approvals: Why Medical Affairs Needs Control

Medical Affairs just revised your IIS review protocols. Perhaps oncology studies now need a different review structure. Maybe compliance thresholds ...
Plain Language Summaries: How AI Helps Medical Affairs Scale

Plain Language Summaries: How AI Helps Medical Affairs Scale

Learn how Medical Affairs teams using governed AI tools are able to meet increasing plain language summary (PLS) expectations without scaling budgets.
Shadow AI in life sciences

Shadow AI in Life Sciences: The Compliance Gap Nobody Talks About

Why ungoverned AI tools are filling the gaps your workflow platform left behind.
How to close pharma's collaboration gap

How to Close Pharma's Collaboration Gap

Why Medical Affairs, Clinical, Regulatory, and Commercial still can't align and what infrastructure actually solves it.
IIS concept reviews by email are chaotic

IIS Concept Review Process: Email Isn't Infrastructure

When was the last time you searched through email threads to find an IIS approval status? If you're like most Medical Affairs professionals, it was ...
Medical Affairs and rapid regulatory shifts

Rapid Regulatory Shifts: How Medical Affairs Can Keep Up

Medical Affairs teams used to have weeks or months to respond to regulatory changes. Now they often only have days (or sometimes just hours).
FDA accelerate approval program guidance

FDA Accelerated Approval Guidance: How Automation Ensures Compliance

The FDA’s Accelerated Approval Program was created to fast-track life-saving drugs for serious diseases, allowing life science companies to bring new ...